Abilify®

Abilify®

ABILIFY® LINKED to COMPULSIVE BEHAVIOR

Popular Medication May Cause Pathological Gambling, Compulsive Shopping, and Binge Eating

According to the FDA, Abillify® (aripiprazole), the top-selling antipsychotic in the United States, has been linked via medical studies to the following intense, compulsive behaviors:

  • Compulsive gambling
  • Compulsive shopping
  • Hyper-sexuality
  • Binge eating

Mostyn Law is evaluating cases in which individuals have sustained serious financial losses through compulsive gambling. Have you or a loved one taken Abilify® and experienced an uncontrollable urge to gamble? Abilify® victims have reported devastating financial losses and damages due to compulsive gambling, including:

  • Draining bank accounts and 401Ks
  • Borrowing money or taking on substantial debt
  • Stealing money/criminal activity
  • Filing for Bankruptcy
  • Foreclosures

If you have accumulated a gambling debt due to an intense, uncontrollable urge to gamble while taking Abilify®, you may have the option to participate in a lawsuit against Bristol-Myers Squibb and Otsuka Pharmaceutical Company. You can receive a free, no obligation, case evaluation from us today. There is never a fee unless we collect for you.

MORE ABOUT ABILIFY®

Abilify® is an anti-psychotic drug developed by Otsuka Pharmaceutical Co., LTD and Otsuka America Phar­maceutical, Inc. Abilify® entered the US market in 2002 after co-opting its development with pharma­ceutical manufacturer Bristol-Myers Squibb. Shortly after introduction, Abilify® became the top-seller in the anti-psychotic medication class and was often prescribed for the following conditions:

  • Schizophrenia
  • Bipolar disorder
  • Depression
  • Autism spectrum disorders
  • Parkinson’s disease.

Although Bristol-Myers Squibb was completely aware of these potentially life-ru­ining side-effects which could result in substantial financial, mental and/or physical damages, it was not until the FDA announced that the Abilify® warnings must be changed that the company finally modified its US packaging, warnings and risk alerts, circa August 2016. The change in the warning states: Post-marketing case reports suggest that patients can experience intense urges, especially for gambling, and the inability to control these urges while taking Abilify®. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask the patient or their caregivers specifically about the develop­ment of new or intense gambling urges or other urges while being taking Abilify®. Urges were reported to have stopped when the dose was reduced or Abilify® was discontinued. Compulsive behaviors may result in harm to the patient and others if not recognized. Read more…

Abilify® lawsuits filed against Bristol-My­ers Squibb and Otsuka allege that the uncontrollable, compulsive behaviors were known prior to the 2016 label change. One lawsuit filed on July 25, 2016, in the United States District Court for the District of Massachusetts, states that the European Medicines Agency required Otsuka to warn patients and the medical community in Europe that the use of Abilify® includes the risk of pathological gambling. Also, the European label includes additional language under the “Unde­sirable Effects” section stating “Psychiatric disorders: agitation, nervousness, pathological gambling, suicide attempt, suicidal ideation and completed suicide.”